EDITORIAL
Preexisting anti-HLA donor-specific antibodies in pediatric renal transplant recipients – A new challenge?
First published: 01 November 2017
No abstract is available for this article.
REFERENCES
- 1Orandi BJ, Luo X, Massie AB, et al. Survival benefit with kidney transplants from HLA-incompatible live donors. N Engl J Med. 2016; 374: 940-950.
- 2Steggerda J, Kim I, Haas M, et al. Clinical and histopathologic features of antibody-mediated rejection among pediatric renal transplant recipients with preformed vs. de novo donor-specific antibodies. Pediatr Transplant. 2017; 21: e13079. https://doi.org/10.1111/petr.13079.
- 3Aubert O, Loupy A, Hidalgo L, et al. Antibody-mediated rejection due to preexisting versus de novo donor-specific antibodies in kidney allograft recipients. J Am Soc Nephrol. 2017; 28: 1912-1923.
- 4Ginevri F, Nocera A, Comoli P, et al. Posttransplant de novo donor-specific HLA antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. Am J Transplant. 2012; 12: 3355-3362.
- 5Tagliamacco A, Cioni M, Comoli P, et al. DQ molecules are the principal stimulators of de novo donor-specific antibodies in nonsensitized pediatric recipients receiving a first kidney transplant. Transpl Int. 2014; 27: 667-673.
- 6Comoli P, Cioni M, Tagliamacco A, et al. Acquisition of C3d-binding activity by de novo donor-specific HLA antibodies correlates with graft loss in nonsensitized pediatric kidney recipients. Am J Transplant. 2016; 16: 2106-2116.
- 7Nocera A, Tagliamacco A, Cioni M, et al. Kidney intragraft homing of de novo donor-specific HLA antibodies is an essential step of antibody-mediated damage but not per se predictive of graft loss. Am J Transplant. 2017; 17: 692-702.
- 8Cioni M, Nocera A, Innocente A, et al. De novo donor-specific HLA antibodies developing early or late after transplant are associated with the same risk of graft damage and loss in nonsensitized kidney recipients. J Immunol Res. 2017; 2017: 1747030.
- 9Smet J, Mascart F, Schandene L. Are the reference values of B cell subpopulations used in adults for classification of common variable immunodeficiencies appropriate for children? Clin Immunol. 2011; 138: 266-273.
